Patent Office throws out Molecular Biosystems' contrast claims
This article was originally published in Clinica
Executive Summary
The US Patent Office has rejected some of the patent claims contested by Molecular Biosystems and its marketing partner, Mallinckrodt, against ImaRx and Dupont Merck Pharmaceutical. Last August MBI attacked the patents held by a number of rival companies in the microsphere ultrasound contrast agent market. The move was seen as a marketing ploy in this fiercely contested and potentially lucrative business sector.